


The following is a complete listing of all claims in the application, with an indication of the status of each:

**Listing of claims:**

1. (Currently amended) A bisacyloxypyrrolycysteine conjugate according to formula (1),



where


$R_1$  and  $R_2$  can be identical or different and are  $C_8$ - $C_{22}$  alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

$Y = -\text{NH}-, -\text{O}-, -\text{S}-, \text{ or } -\text{OCO}-;$


$R_3$  is a ~~covalently, ionically or associatively bonded conjugate radical, in particular a water-soluble and physiologically tolerated, covalently or ionically bonded polymer, in particular covalently bonded polyethylene glycol~~ (polyoxyethylene)  $-(\text{CH}_2-\text{CH}_2-\text{O})_m-\text{CH}_2-\text{CH}_2-\text{X}$ ,

where  $X = \text{OR}, \text{N}[\text{R}]_2, \text{SR} \text{ or } \text{COOR}$ , and

$R = \text{H}, \text{benzyl}-, \text{ or } C_{1-6} \text{ alkyl}$ , where ~~several radicals  $R$ , when  $X = \text{N}[\text{R}]_2$ , the  $[\text{R}]$  groups~~ can be identical or different, ~~a polyoxyethylene-polyoxypropylene copolymer, a dextran, a sugar, a polyvinylpyrrolidone, an alginate, a pectin or a collagen, and where the polymeric radical  $R_3$  is substituted once, twice, or several times by~~



2. (Currently amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that the radicals  $R_{1,2}$ , which can be identical or different, are  $C_{7-25}$ , preferably  $C_{8-22}$ -alkyl, -alkenyl or -alkynyl groups, and wherein the unsaturated positions are preferably in the cis configuration, with the  $C_{8-22}$ -alkyl, alkenyl and alkynyl fatty acid radicals being are branched or unbranched, cyclic or cycloalkyl-substituted radicals.
3. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that the wherein a molecular weight of a water-soluble polymer radical is selected such that it amounts to the covalently bonded polyethylene glycol (polyoxyethylene) -  $(CH_2-CH_2-O)_m-CH_2-CH_2-X$  is from 100 to 30 000 daltons per conjugate molecule.
4. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that the polyethylene glycol of the radical  $R_3$  has a chain length wherein m of is from 5 to 700, ~~preferably of from 100 to 500~~.
5. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that wherein the compound bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol, ~~preferably S-[2,3-bis(palmitoyloxy)-(2s)-propyl]-L-cysteinylcarboxypolyethylene glycol~~.
6. (Currently Amended) ~~A~~ The bisacyloxypropylcysteine conjugate ~~as claimed in~~ of claim 1, characterized in that the compound is a S-[2,3-bis(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol, ~~preferably S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol~~.
7. (Currently Amended) A pharmaceutical composition, comprising a bisacyloxypropylcysteine conjugate ~~as claimed in claim~~ according to formula (1).



where

R<sub>1</sub> and R<sub>2</sub> can be identical or different and are C<sub>8</sub>-C<sub>22</sub> alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

Y = -NH-, -O-, -S-, or -OCO-;

R<sub>3</sub> is a covalently bonded polyethylene glycol (polyoxyethylene) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>m</sub>-CH<sub>2</sub>-CH<sub>2</sub>-X,

where X = OR, N[R]<sub>2</sub>, SR or COOR, and

[R] = H, benzyl-, or C<sub>1-6</sub> alkyl, where, when X = N[R]<sub>2</sub>, the [R] groups can be identical or different.

8. (Currently Amended) The pharmaceutical composition ~~as claimed in~~ of claim 7, ~~characterized in that it comprises pharmaceutical additives or auxiliary substances and; preferably, further comprising~~ a pharmaceutically tolerated excipient.

9. (Currently Amended) The pharmaceutical composition ~~as claimed in~~ of claim 7, wherein the pharmaceutical composition is in the form of a formulation which is suitable for injection, for inhalation or for intranasal or topical administration.

10. (Cancel)

11. (New) The bisacyloxypropylcysteine conjugate of claim 4, wherein m is from 100 to 500.

12. (New) The bisacyloxypropylcysteine conjugate of claim 5, wherein the bisacyloxypropylcysteine conjugate is S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol.


13. (New) The bisacyloxypropylcysteine conjugate of claim 6, wherein the bisacyloxypropylcysteine conjugate is S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.

14. (New) A method of stimulating an immune response to an antigen in an animal or human, comprising the step of

simultaneously administering to the animal or human

the antigen; and

a bisacyloxypropylcysteine conjugate according to formula (1),



where

$\text{R}_1$  and  $\text{R}_2$  can be identical or different and are  $\text{C}_8\text{--C}_{22}$  alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;


$\text{Y} = \text{---NH---}, \text{---O---}, \text{---S---}, \text{or } \text{---OCO---}$ ;

$\text{R}_3$  is a covalently bonded polyethylene glycol (polyoxyethylene)  $\text{---(CH}_2\text{---CH}_2\text{---O)}_m\text{---CH}_2\text{---CH}_2\text{---X}$ ,

where  $\text{X} = \text{OR}, \text{N[R]}_2, \text{SR or COOR}$ , and

$\text{R} = \text{H}, \text{benzyl-}, \text{or } \text{C}_{1\text{--}6} \text{ alkyl}$ , where, when  $\text{X} = \text{N[R]}_2$ , the  $[\text{R}]$  groups can be identical or different.

15. (New) A bisacyloxypropylcysteine conjugate according to formula (1),



where

$R_1$  and  $R_2$  can be identical or different and are  $C_8$ - $C_{22}$  alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

$Y = -NH-$ ,  $-O-$ ,  $-S-$ , or  $-OCO-$ ;


$R_3$  is a covalently bonded polyethylene glycol (polyoxyethylene)  $-(CH_2-CH_2-O)_m-CH_2-CH_2-X$ ,

where  $X = OR$ ,  $N[R]_2$ ,  $SR$  or  $COOR$ , and

$R = H$ , benzyl-, or  $C_{1-6}$  alkyl, where, when  $X = N[R]_2$ , the  $[R]$  groups can be identical or different,

and wherein said bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol.

16. (New) A bisacyloxypropylcysteine conjugate according to formula (1),



where

$R_1$  and  $R_2$  can be identical or different and are  $C_8$ - $C_{22}$  alkyl, alkenyl or alkynyl fatty acid radicals which are bonded by way of the carboxyl group;

$Y = -NH-$ ,  $-O-$ ,  $-S-$ , or  $-OCO-$ ;

$R_3$  is a covalently bonded polyethylene glycol (polyoxyethylene)  $-(CH_2-CH_2-O)_m-CH_2-CH_2-X$ ,

where  $X = OR$ ,  $N[R]_2$ ,  $SR$  or  $COOR$ , and

$R = H$ , benzyl-, or  $C_{1-6}$  alkyl, where, when  $X = N[R]_2$ , the  $[R]$  groups can be identical or different,

and wherein said bisacyloxypropylcysteine conjugate is a S-[2,3-bis(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.